Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Reconstruction of cancer marker analysis with holistic anatomical precision implicates heterogeneity development during breast tumor progression

PROVIDER: PRJNA928368 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23242027_1.fastq.gz	Fastqsanger.gz
	SRR23242027_2.fastq.gz	Fastqsanger.gz
	SRR23242028_1.fastq.gz	Fastqsanger.gz
	SRR23242028_2.fastq.gz	Fastqsanger.gz
	SRR23242029_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

A convolutional neural network STIFMap reveals associations between stromal stiffness and EMT in breast cancer

Project description:Intratumor heterogeneity associates with poor patient outcome. Stromal stiffening also accompanies cancer. Whether cancers demonstrate stiffness heterogeneity, and if this is linked to tumor cell heterogeneity remains unclear. We developed a method to measure the stiffness heterogeneity in human breast tumors that quantifies the stromal stiffness each cell experiences and permits visual registration with biomarkers of tumor progression. We present Spatially Transformed Inferential Force Map (STIFMap) which exploits computer vision to precisely automate atomic force microscopy (AFM) indentation combined with a trained convolutional neural network to predict stromal elasticity with micron-resolution using collagen morphological features and ground truth AFM data. We registered high-elasticity regions within human breast tumors colocalizing with markers of mechanical activation and an epithelial-to-mesenchymal transition (EMT). The findings highlight the utility of STIFMaps to assess mechanical heterogeneity of human tumors across length scales from single cells to whole tissues and implicates stromal stiffness in tumor cell heterogeneity.

2023-04-30 | GSE179983 | GEO

scRNA-seq of pancreatic islets from adult male mice with Fltp-reporter sorting and pancreatic head-tail separation

Project description:Single-cell RNA sequencing of pancreatic islets from adult male mice. To disect islet heterogeneity we sorted cells based on anatomical location and maturity marker (Fltp).

2022-12-23 | GSE211796 | GEO

Proteomic landscape of multi-layered breast cancer internal tumor heterogeneity

Project description:Breast cancer often presents with a high degree of intratumor heterogeneity, resulting in therapy resistance and tumor relapse. Here, we investigated spatial intratumor heterogeneity by integrating histopathological analyses and mass spectrometry-based proteomics. Using multilayered heterogeneity scoring, we identified the proteomic determinants of tumor heterogeneity and associated them with clinical and functional tumor characteristics. We found that molecular subtypes present lower heterogeneity with higher tumor grade, and demonstrate distinct subtype-specific profiles. However, even homogeneous tumors present high degrees of proteomic diversity, associated with proliferative and immune processes. Interestingly, tumor regions from molecularly-heterogeneous tumors, irrespective of their molecular subtype showed high proteomic similarity with enriched glutathione metabolism and proline biosynthesis pathways. Taken together the proteomic analyses revealed the association of internal tumor heterogeneity with cancer progression and immune selection, which can serve as a platform to decipher mechanisms underlying cancer evolution and therapy resistance.

2025-08-10 | PXD024190 | Pride

Single-cell transcriptomics reveals cellular evolution underlying pleomorphic adenoma recurrence and malignant transformation

Project description:Pleomorphic adenoma (PA), the most common benign salivary gland tumor, presents unpredictable risks of recurrence and malignant transformation into carcinoma ex pleomorphic adenoma (CXPA), posing significant clinical challenges. To better delineate the tumor progression trajectory, we performed single-cell RNA sequencing on normal salivary glands, primary PA, recurrent PA (rPA), and CXPA, integrating cell trajectory reconstruction, differential gene expression analysis, and key gene network exploration to uncover molecular transitions and intercellular crosstalk underlying PA recurrence and malignant transformation. Our findings revealed GALNT13⁺ myoepithelial cells as CXPA-specific malignant progenitors, marking early malignant conversion, while MIF⁺ myoepithelial cells exhibited enhanced tissue-destructive capabilities. Fibroblasts played dual roles, enforcing fibrotic restraint in primary PA and promoting extracellular matrix degradation in CXPA. The tumor microenvironment demonstrated stage-specific adaptations, with CXPA favoring pro-inflammatory MIF–CD74/CD44 signaling, whereas rPA adopted immunosuppressive characteristics. Together, stromal reprogramming and immune-editing dynamics orchestrated microenvironmental adaptation, linking cellular heterogeneity to clinical aggressiveness. This study presents the first comprehensive molecular atlas of PA progression, highlighting the malignant specialization of myoepithelial subpopulations, fibroblast-mediated stromal remodeling, and immune-driven microenvironmental evolution, offering a valuable framework for precision stratification of malignant potential and future microenvironment-targeted therapeutic strategies.

2025-04-10 | GSE294254 | GEO

Transcriptional heterogeneity among MDA-MBA-468 triple-negative breast cancer cells

Project description:Intratumoral heterogeneity has been described for various tumor types and models of human cancer, and can have profound effects on tumor progression and drug resistance. This study describes transcriptional heterogeneity among subclonal populations (SCPs) derived from a single triple-negative breast cancer cell line.

2022-01-12 | GSE184542 | GEO

Transcriptional heterogeneity among xenograft tumors derived from subclonal populations of MDA-MBA-468 triple-negative breast cancer cells

2022-01-12 | GSE184541 | GEO

Transcriptional heterogeneity among subclonal populations of MDA-MBA-468 triple-negative breast cancer cells

2022-01-12 | GSE184540 | GEO

In silico reconstruction of primary and metastatic tumor architecture using GIS-augmented spatial transcriptomics

Project description:Tumor microenvironment (TME) consists of different cell populations, whose interactions contribute to tumor heterogeneity and therapy response. Spatial transcriptomics (ST) offers valuable insights into spatial complexity and heterogeneity of TME. We established a Python package, Geographic Information System (GIS)-augmented In-Silico Reconstruction of Tumor Architecture (GIS-ROTA), based on application of GIS methods to ST data to examine/explore spatial heterogeneity of co-regulated gene sets, such as pathways and cell types within the TME. In our Visium dataset of primary and metastatic estrogen receptor positive breast tumor samples, GIS-ROTA revealed extensive co-localization of estrogen response with metabolic pathway gene sets and mutual exclusivity with metastasis-related and specific immune-related pathway gene sets. Our findings demonstrate the robustness of GIS-ROTA in quantitating tumor heterogeneity and identifying spatially significant regions while minimizing the subjectivity involved in interpreting the clusters from conventional statistical methods. Thus, GIS-ROTA enables the development of therapeutic strategies that target multiple cell populations.

2026-02-17 | GSE298286 | GEO

Custom Illumina array DNA methylation analysis of 384 CpGs across five cancer types

Project description:Tumor heterogeneity is a major barrier to effective cancer diagnosis and treatment. We recently identified cancer-specific differentially DNA-methylated regions (cDMRs) in colon cancer, which also distinguish normal tissue types from each other. We therefore hypothesized that these colon cDMRs might also be cDMRs for other cancer types. For colon, lung, breast, thyroid, and Wilms tumors, we show stochastic variation in methylation within each tumor type, but involving the same loci across tumor types, with intermediate values of variation for premalignant adenomas. Seeking to increase the precision of DNA methylation measurements over our previous tiling array-based approach, termed CHARM (Comprehensive High-throughput Array for Relative Methylation), we designed a custom nucleotide-specific bead array on the Illumina GoldenGate platform to analyze 151 colon cDMRs from Irizarry et al. (PMID 19151715). The resulting 384 probes covered 139 regions, with 1-7 probes per region. We studied 290 samples, including cancers from colon (10), lung (24), breast (27), thyroid (36), and kidney (Wilms) (25), with matched normal tissues to 111 of these 122 cancers, along with 30 colon premalignant adenomas, 18 normal colon, and 9 normal breast samples.

2011-06-01 | E-GEOD-29505 | biostudies-arrayexpress

LIMCH1 inhibits antitumor immunity by upregulating PDL1 in triple-negative breast cancer

Project description:Breast cancer is one of the most common malignancies worldwide, with triple-negative breast cancer (TNBC) being a highly aggressive subtype that has shown the greatest benefit from immunotherapy among breast cancer types. LIMCH1, a LIM-domain protein involved in cytoskeletal regulation, has recently been implicated in tumor progression but remains poorly characterized in breast cancer. This study demonstrated that LIMCH1 is overexpressed in breast cancer and associated with poor prognosis. Functional assays revealed that LIMCH1 promotes proliferation and migration while inducing immune evasion through PD-L1 upregulation via the MAPK pathway in TNBC. High LIMCH1 expression correlated with reduced CD4+ and CD8+ T-cell infiltration, an immunosuppressive tumor microenvironment, and lower anti-PD1 therapy efficacy. These findings highlight LIMCH1 as a key driver of tumor progression and immune escape in breast cancer, suggesting its potential as a prognostic biomarker and therapeutic target for precision immunotherapy

2025-12-02 | GSE284738 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data